<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34497136</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1939-327X</ISSN><JournalIssue CitedMedium="Internet"><Volume>70</Volume><Issue>12</Issue><PubDate><Year>2021</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Diabetes</Title><ISOAbbreviation>Diabetes</ISOAbbreviation></Journal><ArticleTitle>Coxsackievirus B Vaccines Prevent Infection-Accelerated Diabetes in NOD Mice and Have No Disease-Inducing Effect.</ArticleTitle><Pagination><StartPage>2871</StartPage><EndPage>2878</EndPage><MedlinePgn>2871-2878</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2337/db21-0193</ELocationID><Abstract><AbstractText>Enteroviruses, including the Coxsackievirus Bs (CVB), have been implicated as causal agents in human type 1 diabetes. Immunization of at-risk individuals with a CVB vaccine provides an attractive strategy for elucidating the role of CVBs in the disease etiology. Previously, we have shown that an inactivated whole-virus vaccine covering all CVB serotypes (CVB1-6) is safe to administer and highly immunogenic in preclinical models, including nonhuman primates. Before initiating clinical trials with this type of vaccine, it was also important to address <i>1</i>) whether the vaccine itself induces adverse immune reactions, including accelerating diabetes onset in a diabetes-prone host, and <i>2</i>) whether the vaccine can prevent CVB-induced diabetes in a well-established disease model. Here, we present results from studies in which female NOD mice were left untreated, mock-vaccinated, or vaccinated with CVB1-6 vaccine and monitored for insulitis occurrence or diabetes development. We demonstrate that vaccination induces virus-neutralizing antibodies without altering insulitis scores or the onset of diabetes. We also show that NOD mice vaccinated with a CVB1 vaccine are protected from CVB-induced accelerated disease onset. Taken together, these studies show that CVB vaccines do not alter islet inflammation or accelerate disease progression in an animal model that spontaneously develops autoimmune type 1 diabetes. However, they can prevent CVB-mediated disease progression in the same model.</AbstractText><CopyrightInformation>&#xa9; 2021 by the American Diabetes Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Stone</LastName><ForeName>Virginia M</ForeName><Initials>VM</Initials><AffiliationInfo><Affiliation>Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Butrym</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hankaniemi</LastName><ForeName>Minna M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sioofy-Khojine</LastName><ForeName>Amir-Babak</ForeName><Initials>AB</Initials><Identifier Source="ORCID">0000-0001-5538-5153</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hyt&#xf6;nen</LastName><ForeName>Vesa P</ForeName><Initials>VP</Initials><AffiliationInfo><Affiliation>Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fimlab Laboratories, Tampere, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hy&#xf6;ty</LastName><ForeName>Heikki</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-0370-4145</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fimlab Laboratories, Tampere, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flodstr&#xf6;m-Tullberg</LastName><ForeName>Malin</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2685-2052</Identifier><AffiliationInfo><Affiliation>Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden malin.flodstrom-tullberg@ki.se.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>figshare</DataBankName><AccessionNumberList><AccessionNumber>10.2337/figshare.16556424</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>09</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Diabetes</MedlineTA><NlmUniqueID>0372763</NlmUniqueID><ISSNLinking>0012-1797</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003384" MajorTopicYN="N">Coxsackievirus Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003922" MajorTopicYN="N">Diabetes Mellitus, Type 1</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029822" MajorTopicYN="N">Enterovirus B, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016688" MajorTopicYN="N">Mice, Inbred NOD</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>3</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>8</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>9</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>9</Month><Day>9</Day><Hour>6</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>9</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34497136</ArticleId><ArticleId IdType="pmc">PMC8660981</ArticleId><ArticleId IdType="doi">10.2337/db21-0193</ArticleId><ArticleId IdType="pii">db21-0193</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>DiMeglio LA, Evans-Molina C, Oram RA. Type 1 diabetes. Lancet 2018;391:2449&#x2013;2462</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6661119</ArticleId><ArticleId IdType="pubmed">29916386</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson SJ, Morgan NG. Enteroviral infections in the pathogenesis of type 1 diabetes: new insights for therapeutic intervention. Curr Opin Pharmacol 2018;43:11&#x2013;19</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6294842</ArticleId><ArticleId IdType="pubmed">30064099</ArticleId></ArticleIdList></Reference><Reference><Citation>Vehik K, Lynch KF, Wong MC, et al. .; TEDDY Study Group . Prospective virome analyses in young children at increased genetic risk for type 1 diabetes. Nat Med 2019;25:1865&#x2013;1872</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6898786</ArticleId><ArticleId IdType="pubmed">31792456</ArticleId></ArticleIdList></Reference><Reference><Citation>Laitinen OH, Honkanen H, Pakkanen O, et al. . Coxsackievirus B1 is associated with induction of &#x3b2;-cell autoimmunity that portends type 1 diabetes. Diabetes 2014;63:446&#x2013;455</Citation><ArticleIdList><ArticleId IdType="pubmed">23974921</ArticleId></ArticleIdList></Reference><Reference><Citation>Oikarinen S, Martiskainen M, Tauriainen S, et al. . Enterovirus RNA in blood is linked to the development of type 1 diabetes. Diabetes 2011;60:276&#x2013;279</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3012181</ArticleId><ArticleId IdType="pubmed">20943747</ArticleId></ArticleIdList></Reference><Reference><Citation>Salminen K, Sadeharju K, L&#xf6;nnrot M, et al. . Enterovirus infections are associated with the induction of beta-cell autoimmunity in a prospective birth cohort study. J Med Virol 2003;69:91&#x2013;98</Citation><ArticleIdList><ArticleId IdType="pubmed">12436483</ArticleId></ArticleIdList></Reference><Reference><Citation>Stene LC, Oikarinen S, Hy&#xf6;ty H, et al. . Enterovirus infection and progression from islet autoimmunity to type 1 diabetes: the Diabetes and Autoimmunity Study in the Young (DAISY). Diabetes 2010;59:3174&#x2013;3180</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2992780</ArticleId><ArticleId IdType="pubmed">20858685</ArticleId></ArticleIdList></Reference><Reference><Citation>Horwitz MS, Bradley LM, Harbertson J, Krahl T, Lee J, Sarvetnick N. Diabetes induced by Coxsackie virus: initiation by bystander damage and not molecular mimicry. Nat Med 1998;4:781&#x2013;785</Citation><ArticleIdList><ArticleId IdType="pubmed">9662368</ArticleId></ArticleIdList></Reference><Reference><Citation>Larsson PG, Lakshmikanth T, Laitinen OH, et al. . A preclinical study on the efficacy and safety of a new vaccine against coxsackievirus B1 reveals no risk for accelerated diabetes development in mouse models. Diabetologia 2015;58:346&#x2013;354</Citation><ArticleIdList><ArticleId IdType="pubmed">25370797</ArticleId></ArticleIdList></Reference><Reference><Citation>Serreze DV, Ottendorfer EW, Ellis TM, Gauntt CJ, Atkinson MA. Acceleration of type 1 diabetes by a coxsackievirus infection requires a preexisting critical mass of autoreactive T-cells in pancreatic islets. Diabetes 2000;49:708&#x2013;711</Citation><ArticleIdList><ArticleId IdType="pubmed">10905477</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunne JL, Richardson SJ, Atkinson MA, et al. . Rationale for enteroviral vaccination and antiviral therapies in human type 1 diabetes. Diabetologia 2019;62:744&#x2013;753</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6450860</ArticleId><ArticleId IdType="pubmed">30675626</ArticleId></ArticleIdList></Reference><Reference><Citation>Hy&#xf6;ty H, Leon F, Knip M. Developing a vaccine for type 1 diabetes by targeting coxsackievirus B. Expert Rev Vaccines 2018;17:1071&#x2013;1083</Citation><ArticleIdList><ArticleId IdType="pubmed">30449209</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone VM, Hankaniemi MM, Laitinen OH, et al. . A hexavalent coxsackievirus B vaccine is highly immunogenic and has a strong protective capacity in mice and nonhuman primates. Sci Adv 2020;6:eaaz2433.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7202868</ArticleId><ArticleId IdType="pubmed">32494709</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone VM, Hankaniemi MM, Svedin E, et al. . A coxsackievirus B vaccine protects against virus-induced diabetes in an experimental mouse model of type 1 diabetes. Diabetologia 2018;61:476&#x2013;481</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6448957</ArticleId><ArticleId IdType="pubmed">29151123</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultz NH, S&#xf8;rvoll IH, Michelsen AE, et al. . Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med 2021;384:2124&#x2013;2130</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8112568</ArticleId><ArticleId IdType="pubmed">33835768</ArticleId></ArticleIdList></Reference><Reference><Citation>Segal Y, Shoenfeld Y. Vaccine-induced autoimmunity: the role of molecular mimicry and immune crossreaction. Cell Mol Immunol 2018;15:586&#x2013;594</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6078966</ArticleId><ArticleId IdType="pubmed">29503439</ArticleId></ArticleIdList></Reference><Reference><Citation>Roivainen M, Knip M, Hy&#xf6;ty H, et al. . Several different enterovirus serotypes can be associated with prediabetic autoimmune episodes and onset of overt IDDM. Childhood Diabetes in Finland (DiMe) Study Group. J Med Virol 1998;56:74&#x2013;78</Citation><ArticleIdList><ArticleId IdType="pubmed">9700636</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullen Y. Development of the nonobese diabetic mouse and contribution of animal models for understanding type 1 diabetes. Pancreas 2017;46:455&#x2013;466</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5359790</ArticleId><ArticleId IdType="pubmed">28291161</ArticleId></ArticleIdList></Reference><Reference><Citation>Sioofy-Khojine AB, Lehtonen J, Nurminen N, et al. . Coxsackievirus B1 infections are associated with the initiation of insulin-driven autoimmunity that progresses to type 1 diabetes. Diabetologia 2018;61:1193&#x2013;1202</Citation><ArticleIdList><ArticleId IdType="pubmed">29404673</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xe4;m&#xe4;l&#xe4;inen S, Nurminen N, Ahlfors H, et al. . Coxsackievirus B1 reveals strain specific differences in plasmacytoid dendritic cell mediated immunogenicity. J Med Virol 2014;86:1412&#x2013;1420</Citation><ArticleIdList><ArticleId IdType="pubmed">24616040</ArticleId></ArticleIdList></Reference><Reference><Citation>Flodstr&#xf6;m M, Maday A, Balakrishna D, Cleary MM, Yoshimura A, Sarvetnick N. Target cell defense prevents the development of diabetes after viral infection. Nat Immunol 2002;3:373&#x2013;382</Citation><ArticleIdList><ArticleId IdType="pubmed">11919579</ArticleId></ArticleIdList></Reference><Reference><Citation>McCall KD, Thuma JR, Courreges MC, et al. . Toll-like receptor 3 is critical for coxsackievirus B4-induced type 1 diabetes in female NOD mice. Endocrinology 2015;156:453&#x2013;461</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4298321</ArticleId><ArticleId IdType="pubmed">25422874</ArticleId></ArticleIdList></Reference><Reference><Citation>Serreze DV, Wasserfall C, Ottendorfer EW, et al. . Diabetes acceleration or prevention by a coxsackievirus B4 infection: critical requirements for both interleukin-4 and gamma interferon. J Virol 2005;79:1045&#x2013;1052</Citation><ArticleIdList><ArticleId IdType="pmc">PMC538592</ArticleId><ArticleId IdType="pubmed">15613333</ArticleId></ArticleIdList></Reference><Reference><Citation>Flodstr&#xf6;m M, Tsai D, Fine C, Maday A, Sarvetnick N. Diabetogenic potential of human pathogens uncovered in experimentally permissive beta-cells. Diabetes 2003;52:2025&#x2013;2034</Citation><ArticleIdList><ArticleId IdType="pubmed">12882919</ArticleId></ArticleIdList></Reference><Reference><Citation>Hankaniemi MM, Laitinen OH, Stone VM, et al. . Optimized production and purification of Coxsackievirus B1 vaccine and its preclinical evaluation in a mouse model. Vaccine 2017;35:3718&#x2013;3725</Citation><ArticleIdList><ArticleId IdType="pubmed">28579231</ArticleId></ArticleIdList></Reference><Reference><Citation>
Provention Bio . Provention Bio Initiates First-in-Human Study of Coxsackievirus B Vaccine Candidate PRV-101. 15 December 2020. Accessed 5 March 2021. Available from https://investors.proventionbio.com/2020-12-15-Provention-Bio- Initiates-First-in-Human-Study-of-Coxsackievirus-B-Vaccine-Candidate- PRV-101</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>